Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Identification of Biological Predictive Factors of Clinical Response to Ustekinumab in Patients With Anti-Tumor Necrosis Factor (TNF) Antagonists Refractory Crohn's Disease: Interest of Dosage of C Reactive Protein (CRP), Calprotectin, Ustekinumab Through Levels and Antibodies

Trial Profile

Identification of Biological Predictive Factors of Clinical Response to Ustekinumab in Patients With Anti-Tumor Necrosis Factor (TNF) Antagonists Refractory Crohn's Disease: Interest of Dosage of C Reactive Protein (CRP), Calprotectin, Ustekinumab Through Levels and Antibodies

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Crohn's disease
  • Focus Pharmacodynamics
  • Acronyms SAFARI
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 08 Feb 2018 Planned End Date changed from 1 Mar 2018 to 1 Aug 2018.
    • 08 Feb 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top